Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E131.49 EPS (ttm)1.24 Insider Own4.10% Shs Outstand60.22M Perf Week1.34%
Market Cap9.82B Forward P/E16.17 EPS next Y10.09 Insider Trans-21.84% Shs Float58.09M Perf Month16.69%
Income81.70M PEG6.07 EPS next Q2.22 Inst Own87.60% Short Float3.20% Perf Quarter13.04%
Sales1.01B P/S9.76 EPS this Y-19.10% Inst Trans0.33% Short Ratio2.20 Perf Half Y1.45%
Book/sh21.50 P/B7.58 EPS next Y23.20% ROA3.00% Target Price181.89 Perf Year85.94%
Cash/sh4.46 P/C36.60 EPS next 5Y21.65% ROE6.50% 52W Range80.40 - 176.60 Perf YTD28.83%
Dividend- P/FCF29.87 EPS past 5Y20.00% ROI13.30% 52W High-7.67% Beta0.81
Dividend %- Quick Ratio2.60 Sales past 5Y66.80% Gross Margin88.90% 52W Low102.80% ATR4.88
Employees830 Current Ratio2.80 Sales Q/Q39.80% Oper. Margin26.20% RSI (14)65.14 Volatility2.08% 3.81%
OptionableYes Debt/Eq0.93 EPS Q/Q1.40% Profit Margin8.10% Rel Volume0.76 Prev Close162.92
ShortableYes LT Debt/Eq0.93 EarningsAug 05 AMC Payout0.00% Avg Volume845.24K Price163.05
Recom1.80 SMA209.10% SMA509.60% SMA20015.87% Volume642,390 Change0.08%
09-May-14Reiterated R. F. Lafferty Neutral $140 → $130
17-Apr-14Initiated Canaccord Genuity Buy $163
07-Mar-14Resumed Barclays Overweight $200
26-Feb-14Reiterated Stifel Buy $145 → $195
14-Jan-14Reiterated UBS Buy $130 → $164
14-Jan-14Downgrade R. F. Lafferty Buy → Neutral $140
06-Dec-13Reiterated UBS Buy $110 → $130
25-Nov-13Reiterated FBR Capital Outperform $105 → $198
25-Nov-13Reiterated Barclays Overweight $112 → $130
13-Nov-13Reiterated R. F. Lafferty Buy $102 → $118
30-Oct-13Initiated FBR Capital Outperform $105
13-Sep-13Reiterated UBS Buy $87 → $98
22-Aug-13Initiated R. F. Lafferty Buy $102
07-Aug-13Reiterated UBS Buy $80 → $87
07-Aug-13Reiterated Cantor Fitzgerald Buy $86 → $97
07-Aug-13Reiterated Barclays Overweight $70 → $85
31-May-13Initiated Stifel Buy $80
11-Mar-13Initiated Cantor Fitzgerald Buy $86
27-Feb-13Reiterated UBS Buy $64 → $67
23-May-12Initiated Oppenheimer Outperform $66
02-Sep-14 07:00AM  Get that shopping list ready to buy on the dip at CNBC
29-Aug-14 06:49PM  Baidu, AerCap And Jazz Among Basing Top World Stocks at Investor's Business Daily
27-Aug-14 08:02AM  Gilead, Jazz Among 4 Top Big Cap Medicals To Watch at Investor's Business Daily
21-Aug-14 08:07AM  Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue? Zacks
20-Aug-14 05:29PM  Allergan Talks to Buy Salix in Defense Move Said to Be Dormant at Bloomberg
01:11PM  Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up at Investor's Business Daily
09:38AM  [video] Faber Report: WSJ says Allergan approaches Salix at CNBC
19-Aug-14 05:03PM  Indexes Rally On Strong Housing Data, Retail Reports at Investor's Business Daily
03:13PM  Stocks Add To Gains; Salix Surges On Potential Bid at Investor's Business Daily
02:02PM  JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition' Benzinga
12:54PM  Why Jazz Pharmaceuticals (JAZZ) Stock Is Gaining Today at TheStreet
09:27AM  Will This Coverage Initiation Help Jazz Pharmaceuticals (JAZZ) Stock Today? at TheStreet
18-Aug-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
15-Aug-14 11:48AM  Stocks Backslide Into Losses; Jazz Pharma, Kinder Morgan Rise at Investor's Business Daily
09:51AM  Jazz Pharmaceuticals (JAZZ) Is Today's Momo Momentum Stock at TheStreet
14-Aug-14 07:02AM  Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% Zacks
13-Aug-14 04:36PM  [video] Airline Stocks Soar, Boosting U.S. Stock Market Rally at TheStreet +8.81%
04:36PM  [video] Airline Stocks Soar Boosting U.S. Stock Market Rally at TheStreet
04:10PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi EDGAR Online
03:55PM  Watch Out: Barbarians At The Gate For Jazz Pharmaceuticals (JAZZ) at TheStreet
01:29PM  Nasdaq Leads Indexes As Solar, Biotechs Outperform at Investor's Business Daily
11:12AM  Jazz Pharmaceuticals PLC Stock Upgraded (JAZZ) at TheStreet
12-Aug-14 01:04PM  JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials
06:41AM  Why Jazz Pharmaceuticals (JAZZ) Could Be an Impressive Growth Stock Zacks
08-Aug-14 04:34PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10:29AM  Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The Wall Street Transcript Wall Street Transcript
06:30AM  Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes PR Newswire
07-Aug-14 04:20PM  Afternoon Selling Holds Stocks In Check at Investor's Business Daily -5.18%
10:23AM  Jazz Financing I Ltd. -- Moody's upgrades Jazz credit facilities to Ba2; affirms Ba3 CFR at Moody's
07:32AM  Jazz Pharmaceuticals (JAZZ) Jumps: Stock Moves 5.2% Higher Zacks
07:00AM  3 Big-Volume Biotech Stocks to Trade for Breakouts at TheStreet
06-Aug-14 05:13PM  Roses in the Market Yahoo Finance Blogs +5.18%
05:07PM  Stocks Muted; Keurig Green Mountain Down After Hours at Investor's Business Daily
04:17PM  Indexes Close Flat After Seesaw Session at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes PR Newswire
01:36PM  Jazz Pharma Jumps After Q2 Earnings Rebound at Investor's Business Daily
10:13AM  Barbarian At The Gate: Jazz Pharmaceuticals (JAZZ) at TheStreet
09:33AM  Jazz Pharmaceuticals Spikes In #PreMarket On Q2 Beat; Boosts Revenue Outlook Benzinga
08:30AM  Earnings Up at Jazz Pharmaceuticals, Revenue Guidance Raised Zacks
05-Aug-14 04:49PM  Ukraine Jitters Send Stocks Lower In Afternoon Trade at Investor's Business Daily
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Point Digit Loss; S&P 500 & Nasdaq Also Lower Benzinga
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:28PM  Stocks Fall In Fast Trade; First Solar Down On Earnings at Investor's Business Daily
04:25PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements EDGAR Online
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance PR Newswire
04:01PM  Jazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. PR Newswire
02:14PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
10:29AM  Actavis Guidance Disappoints; Akorn Beats And Raises at Investor's Business Daily
07:34AM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q2 2014 Jazz Pharmaceuticals Earnings Release - After Market Close CCBN
04-Aug-14 04:10PM  Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13 PR Newswire
02-Aug-14 08:02AM  Salix, Actavis Lead IBD 50 Drug Earnings This Week at Investor's Business Daily
01-Aug-14 08:41AM  The Zacks Analyst Blog Highlights: Medtronic, Covidien, Mylan, Actavis and Jazz Pharmaceuticals Zacks
30-Jul-14 05:33PM  A Cup-With-Handle Breakout Can Lead To Massive Gains Investor's Business Daily
23-Jul-14 09:05PM  Are P/E Ratios Leading You Away From Your Biggest Winners? at Seeking Alpha
22-Jul-14 04:25PM  Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study Zacks
04:05PM  Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 PR Newswire
21-Jul-14 04:05PM  Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 Business Wire
01:52PM  Your Best Wealth-Building Choice From Today's Top Market-Maker Price Range Forecasts at Seeking Alpha
01:02PM  3 Stocks Moving The Health Care Sector Upward at TheStreet
14-Jul-14 06:56PM  Irish Stocks Come To Prominence As Taxes Stay Low at Investor's Business Daily
10-Jul-14 12:07PM  Market Slides On European Bank Worries; Gold Stocks Rise at Investor's Business Daily
08:20AM  The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks
09-Jul-14 11:14AM  Salix Pharma Stock Falls Despite Tax-Inversion Deal at Investor's Business Daily
10:40AM  Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Zacks
08:15AM  Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal Zacks
08-Jul-14 04:10PM  Raptor Pharmaceuticals CEO to Retire, Appoints Successor Zacks
06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events EDGAR Online
07-Jul-14 06:18PM  Jazz, Novo Among Medicals Showing Healthy Action at Investor's Business Daily
01:41PM  Stocks Add To Losses; TAL Education Bucks Weakness at Investor's Business Daily
03-Jul-14 06:26PM  Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week at Investor's Business Daily
06:26PM  Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week at Investor's Business Daily
04:10PM  Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up Zacks
08:09AM  Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher Zacks
02-Jul-14 04:17PM  Stocks End Mixed In Light Trade As Jobs Report Looms at Investor's Business Daily +6.97%
03:09PM  Stocks Nearly Flat In Quiet Trading With 1 Hour To Go at Investor's Business Daily
02:41PM  Watch Out: Barbarians At The Gate For Jazz Pharmaceuticals (JAZZ) at TheStreet
01:54PM  Jazz Pharma Buys Out Rights To Newly Acquired Drug at Investor's Business Daily
08:12AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online
08:00AM  Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. PR Newswire
24-Jun-14 10:28AM  Of These 3 Battleground Biotech Stocks, 1 Is a Buy
23-Jun-14 06:14AM  Momentum bulls return to Jazz optionMONSTER
06:14AM  Momentum bulls return to Jazz
21-Jun-14 10:34AM  The 3 Best Tax Havens for Health Care Companies at Motley Fool
10:34AM  The 3 Best Tax Havens for Health Care Companies
19-Jun-14 06:50PM  Lightning Round: Chiptole, Gilead & more at CNBC
06:50PM  Lightning Round: Chiptole, Gilead & more
05:02PM  Is This Jazz Pharmaceuticals' Worst Nightmare? at Motley Fool
05:02PM  Is This Jazz Pharmaceuticals' Worst Nightmare?
18-Jun-14 06:34PM  M&A Activity Helps Fuel Healthy Action In Drugmakers at Investor's Business Daily
06:34PM  M&A Activity Helps Fuel Healthy Action In Drugmakers
09:42AM  Why Jazz Pharmaceuticals Is an Attractive Buyout Candidate at Motley Fool
09:42AM  Why Jazz Pharmaceuticals Is an Attractive Buyout Candidate
16-Jun-14 05:45PM  Mid-June Equities With Best Wealth-Building Odds, Big Rates Of Gain In Next 6 Months at Seeking Alpha
12-Jun-14 05:00PM  Stephen Mandels Lone Pine Capital sells its shares in Dollar Tree Market Realist
05:00PM  Stephen Mandels Lone Pine Capital sells its shares in Dollar Tree
01:00PM  Lone Pine Capital buys a new stake in Jazz Pharmaceuticals Market Realist
01:00PM  Lone Pine Capital buys a new stake in Jazz Pharmaceuticals
11-Jun-14 01:00PM  Lone Pine Capital buys a new position in LPL Financial Holdings Market Realist
10-Jun-14 03:37PM  Must-know update: Lone Pine Capitals positions in 1Q 2014 Market Realist
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hooper Suzanne SawochkaEVP and General CounselAug 15Option Exercise46.8366731,23652,471Aug 19 07:04 PM
Hooper Suzanne SawochkaEVP and General CounselAug 15Sale150.00667100,05051,804Aug 19 07:04 PM
Winningham Rick EDirectorAug 12Sale133.151,087144,73414,150Aug 14 06:08 PM
Sohn Catherine A.DirectorAug 12Sale133.151,731230,4835,529Aug 14 06:07 PM
ENRIGHT PATRICK GDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:03 PM
BERNS PAUL LDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:01 PM
Hooper Suzanne SawochkaEVP and General CounselAug 12Sale133.151,185157,78351,804Aug 13 06:37 PM
COZADD BRUCE CChairman and CEOAug 12Sale133.155,000665,750579,023Aug 13 06:33 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Option Exercise52.744,933260,18847,471Aug 13 06:51 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Sale135.424,933668,02742,538Aug 13 06:51 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Option Exercise46.831,85386,77659,407Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Option Exercise46.8346921,96333,741Jul 10 08:14 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Sale155.001,853287,21557,554Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Sale155.001,991308,60531,750Jul 10 08:14 PM
COZADD BRUCE CChairman and CEOJul 08Sale155.005,000775,000597,067Jul 10 08:04 PM
WILSON KAREN JSVP, Finance & PAOJul 07Option Exercise27.462,50068,65026,169Jul 09 08:12 PM
WILSON KAREN JSVP, Finance & PAOJul 07Sale165.002,500412,50023,669Jul 09 08:12 PM
Mulligan SeamusDirectorJun 25Sale148.64476,9861,405,555Jun 26 08:21 PM
Mulligan SeamusDirectorJun 24Sale149.7049,9537,477,7491,405,602Jun 26 08:21 PM
Cox Russell J.EVP & Chief Operating OfficerJun 20Sale155.002,000310,00057,032Jun 24 07:06 PM
Keegan FintanEVP, Technical OperationsJun 17Sale150.003,750562,50033,272Jun 19 04:01 PM
COZADD BRUCE CChairman and CEOJun 10Sale142.345,000711,700602,067Jun 11 04:36 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Option Exercise48.633,000145,89050,103Jun 11 06:30 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Sale146.243,000438,72047,103Jun 11 06:30 PM
RIEDEL NORBERT GDirectorMay 28Sale142.4964491,7643,356May 29 07:27 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Option Exercise46.8366731,23657,802May 29 07:24 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Sale140.0066793,38057,135May 29 07:24 PM
COZADD BRUCE CChairman and CEOMay 13Sale128.925,000644,600606,810May 14 06:09 PM
Keegan FintanEVP, Technical OperationsMay 08Sale136.03750102,02337,772May 12 08:13 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Option Exercise46.8366731,23657,802Apr 21 07:59 PM
Winningham Rick EDirectorApr 17Sale140.0027,5003,850,00013,587Apr 21 07:55 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Sale140.0066793,38057,135Apr 21 07:59 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Option Exercise53.883,000161,64651,103Apr 16 07:41 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Sale128.543,000385,62048,103Apr 16 07:41 PM
Keegan FintanEVP, Technical OperationsApr 08Sale130.0075097,50038,522Apr 10 08:37 PM
COZADD BRUCE CChairman and CEOApr 08Sale123.185,000615,900611,810Apr 10 08:34 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Option Exercise53.883,000161,63451,103Mar 12 06:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Sale152.993,000458,97048,103Mar 12 06:06 PM
WILSON KAREN JSVP, Finance & PAOMar 07Option Exercise59.133,000177,39027,300Mar 11 08:26 PM
WILSON KAREN JSVP, Finance & PAOMar 07Sale155.043,888602,79623,412Mar 11 08:26 PM
Keegan FintanEVP, Technical OperationsMar 06Sale157.891,634257,99239,272Mar 06 07:01 PM
Keegan FintanEVP, Technical OperationsMar 04Sale161.003,006483,96640,906Mar 06 07:01 PM
Mulligan SeamusDirectorMar 04Sale156.25550,00085,937,5001,455,555Mar 05 05:19 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Option Exercise46.8311,250526,83832,582Mar 03 08:14 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Sale166.7711,2501,876,15021,332Mar 03 08:14 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 27Sale165.463,000496,38041,777Mar 03 08:05 PM
COZADD BRUCE CChairman and CEOFeb 27Sale158.3625,0003,959,000600,754Mar 03 07:21 PM
Cox Russell J.EVP & Chief Commercial OfficerFeb 27Sale164.594,000658,36050,024Mar 03 07:10 PM
FALBERG KATHRYN EEVP and CFOFeb 26Option Exercise7.3510,20474,999134,925Feb 27 08:08 PM
FALBERG KATHRYN EEVP and CFOFeb 12Sale157.002,000314,000124,721Feb 14 07:09 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Option Exercise46.832,560119,88547,337Feb 12 07:18 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Sale152.832,560391,24544,777Feb 12 07:18 PM
FALBERG KATHRYN EEVP and CFOJan 08Sale131.822,000263,640126,721Jan 10 08:26 PM
FALBERG KATHRYN EEVP and CFODec 11Sale120.503,000361,500128,721Dec 13 07:49 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Option Exercise46.831,32562,05046,102Dec 11 07:01 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Sale117.801,325156,08544,777Dec 11 07:01 PM
FALBERG KATHRYN EEVP and CFONov 13Sale100.883,000302,640131,372Nov 15 06:16 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Option Exercise46.832,373111,12846,778Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Sale98.502,373233,74144,405Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Option Exercise46.835,000234,15049,405Oct 16 06:54 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Sale82.625,000413,11844,405Oct 16 06:54 PM
FALBERG KATHRYN EEVP and CFOOct 09Sale83.103,000249,300134,372Oct 11 06:55 PM
COZADD BRUCE CChairman and CEOOct 08Sale88.584,000354,320625,647Oct 10 06:28 PM
FALBERG KATHRYN EEVP and CFOSep 11Sale87.523,000262,560137,372Sep 13 05:56 PM
COZADD BRUCE CChairman and CEOSep 10Sale87.595,000437,950629,647Sep 10 06:11 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Option Exercise46.835,000234,15049,405Sep 10 06:03 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Sale87.115,000435,55044,405Sep 10 06:03 PM
Cox Russell J.EVP & Chief Commercial OfficerSep 04Sale88.161,00088,16052,736Sep 04 05:48 PM